GeneDx shares rise after Q4 results beat estimates

GeneDx Holdings

23/02/2026 12:54

** Shares of genetic testing company GeneDx Holdings WGS.O rise nearly 3% to $84.50 premarket

** Co posts Q4 revenue of $121 million, compared with analysts' estimate of $120.4 million, according to data compiled by LSEG

** Co posts Q4 adjusted profit of 14 cents per share vs analysts' estimates of 11 cents per share -LSEG

** Revenue from its exome and genome tests grew 32% to $104 million in Q4 - WGS

** WGS reaffirms FY26 revenue outlook of $540 to $555 million, with 33-35% growth in exome and genome test revenue

** "We believe GeneDx has a unique first-mover advantage in a fast-growing and expanding market in rare disease testing" - Piper Sandler analysts

** WGS shares had risen over 69% in 2025

 (Reporting by Kunal Das in Bengaluru)

 ((Kunal.Das2@thomsonreuters.com;))